Developing new antibiotics to fight drug-resistant bacteria
Bactericidal antibiotics targeting lipoprotein transport in Gram-negative bacteria
This study is working on developing new antibiotics to help fight tough bacteria like E. coli and K. pneumoniae that don't respond to regular treatments, making it easier for people to get better when they have infections.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Harvard University NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project ID | NIH-11029445 on NIH RePORTER |
What this research studies
This research focuses on creating new antibiotics to combat multi-drug resistant (MDR) bacteria, specifically targeting E. coli and K. pneumoniae. The approach involves modifying existing antibiotic structures to enhance their effectiveness and reduce the likelihood of bacteria developing resistance. The team will synthesize a variety of antibiotic candidates and test their potency and safety through laboratory studies. Additionally, advanced imaging techniques will be used to understand how these antibiotics interact with bacterial transport systems, which will guide the design of future treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from infections caused by multi-drug resistant bacteria, particularly those involving E. coli and K. pneumoniae.
Not a fit: Patients with infections caused by non-gram-negative bacteria or those not affected by antibiotic resistance may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective antibiotics that can treat infections caused by drug-resistant bacteria.
How similar studies have performed: Previous research has shown promise in developing antibiotics targeting bacterial transport mechanisms, indicating potential for success in this novel approach.
Where this research is happening
Cambridge, United States
- Harvard University — Cambridge, United States (Active)
Researchers
- Principal investigator: Myers, Andrew G — Harvard University
- Study coordinator: Myers, Andrew G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.